ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncol...(set forth in this pressrelease to reflec...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:3/12/2008
set forth in this press release to reflect events or circumstances arising after the date on which it was made.
'/>"/>
| SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
2. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Genzyme Announces Presentation of New Positive Data on Carticel(R)
7. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
8. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
9. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Post Your Comments:
(Date:11/21/2008)....J., Nov. 21 Ikaria Holdings, Inc....mpany of the Year by the New Jersey Technology Cou...n that provides business support, networking oppor...companies and their leaders. Ikaria earned the awa...nd unique product/service provision. , , "W...
(Date:11/20/2008)... , , PHILADELPHIA, Nov. 20 /PRNewswire-Fi...nounced that the United States Food and Drug Admin...ROMACTA(R) (eltrombopag) for the treatment of thro...pathic) thrombocytopenic purpura (ITP) who have ha...unoglobulins or splenectomy. The approval is a sig...
(Date:11/20/2008)..., Calif., Nov. 20 Bionov...ill present results from the Phase 1B,clinical tr...static breast,cancer, BZL101, at the Society for ...ence in Atlanta, Georgia. The Company,s oral pres...nd will be presented as a part of the Best of the,...
(Date:11/20/2008)...v. 20 PAREXEL Internatio...l biopharmaceutical services provider, today annou... provide regulatory consulting and clinical resear...ice, PAREXEL now has locations throughout five imp... which also include Argentina, Brazil, Chile, and ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 1KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 2KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 3KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 4KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva 28TM 29 9941 5LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 1LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 2DNA sensors found to be an effective artificial nose 2696 1Stroke Undertreated 9939 1Stroke Undertreated 9939 2Stroke Undertreated 9939 3[0] Ikaria(R) Named Private Company of the Year by New Jersey Technology Council[0] FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder[0] Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology[0] PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
...od and Drug,Administration (FDA) today issued the ...nitiatives/criticalpath/reports/generic.html">Crit... identifying many,of the unanswered scientific que...ions of commonly used drugs. , The report is part ...2004 to discern what challenges exist in moving a,...
...eNeS Pharmaceuticals plc,(LSE: CEN), the Cambridge...that the United States Food and Drug Administratio...(IND) application for the,clinical development of ...he treatment of post-operative pain. Earlier this ... of M6G in Europe in,over 500 patients with post-o...
Other Medicine Technology:New Critical Path Report Highlights Research Needed to Foster,Generic Drug Development 2FDA approves IND on Lead Product M6G 2(Date:11/21/2008)...als showed Banzel proved effective against Lennox-...althDay News) -- A new drug called Banzel (rufinam...t for a severe form of epilepsy called Lennox-Gast...n announced Friday. , The approval was based on...ded patients ages 4 to 30. Compared to patients wh...
(Date:11/21/2008)...LADELPHIA, Nov. 21 NursingCenter.c...g education and peer reviewed content, has been,u...ts 350,000 registered,users. Powered by Lippincot...now,provides over 900 peer-reviewed continuing ed...cles from more than 50 leading nursing journals.,...
(Date:11/21/2008)...NKLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstCall/ ...for medical intervention in treating 88 percent of...rcent of Americans treated for a chronic condition...pending and 75 percent of all medical costs. A pr...years by Medco Health Solutions, Inc. (NYSE: MHS...
(Date:11/21/2008)...n 430 B.C., a new and deadly diseaseits cause rema...ity-state was teeming with citizens, soldiers and ... Sparta. As streets filled with corpses, social or...ness returned twice and Athens lost a third of its...hens marked the beginning of the end of the Golden...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4[0] FDA Approves New Drug for Severe Epilepsy[0] NursingCenter.com Launches New Features to Improve User Experience[0] New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes[1] Study of ancient and modern plagues finds common features
...confirmed a link between exercising and the preven...a study conducted researchers gathered results fro...0 to 69. Participants were asked about the level o...ent and adult years.Results show women who exercis...
...hat a few alcoholic beverages a month may reduce t...n // with high blood pressure. Researchers found w...ificantly lower risk of death by nearly 30 percent... also a reduced risk of cardiovascular disease dea...
... survival rate of breast cancer patients by 63 per...rd regimes available . The clinical trial strength...mestane, as a first option.// A study showed that ... chance of developing another tumor by 32 percent ...
...lition of Health for Asthmatics in Sports and Exer...ave an exercise test // to 127, 6- to 18-year ol...sk factors were determined by a 10-item questionna...n was a family member having allergies or asthma. ...
Other Medicine News:...cal IOL is a foldable silicone IOL. It features a ...e inserted with The UNFOLDER® Silver-T Implant... first and only FDA-approved multifocal IOL, and t...nal visionnear, intermediate, and far. The ARRAY&r...
...ferred viscoelastic for phacoemulsification proced...rks from the start to the finish of the case. The ...lastic is the reason. The low to moderate vacuum f...nly a fraction of the viscoelastic agent. However,...
...scoelastic agent for the surgeon who performs cata... Amvisc possesses sufficient viscosity for excelle... is highly cohesive so that complete removal at th...ed. Amvisc is priced to compete with any sodium hy...
...onate (1.8%) viscoelastic solution combines maximu...flo maintains a deep anterior chamber and protects... ideal for routine cataract surgery but can be use...lastic. Combine all these properties with the conv...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |